Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
Part of paid clinical trials in Stanford, California.
- Sponsor
- Comprehensive Research Associates
- Study ID
- NCT04443608
- Phase
- PHASE4
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Patiromer Powder for Oral Suspension [Veltassa] — DRUGPowder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
- Placebo — DRUGPowder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
Study Details
When a patient arrives to an emergency department and is found to have an elevated potassium level in the blood, there is no one standardized treatment, therefore it is not known if one treatment is superior to other. The purpose of this study is to help determine if a drug called patiromer (already approved by the FDA) can help lower potassium levels while patients are in the emergency department.
Key Dates
- Start date
- Oct 8, 2020
- Status verified
- Apr 2023
- Primary completion
- Mar 9, 2023
- Completion
- Jun 3, 2023
Study Design
- Enrollment
- 115 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Veltassa3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
- Placebo Comparator: Placebo3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
Primary Outcome Measure
The need for additional potassium-lowering medical interventions [ Time Frame: Duration of patient's emergency department visit, up to 6 hours ]
Locations (19)
Find similar trials in Stanford, CA
Related Studies
- Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of AgePHASE2 · Recruiting · Vifor Pharma, Inc. · Aurora, Colorado
- Adding Urea to the Final Dialysis FluidPHASE1/PHASE2 · Recruiting · University of California, San Francisco · San Francisco, California
- COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG WearableEnrolling By Invitation · Peerbridge Health, Inc · Melbourne, Florida
- AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote MonitoringRecruiting · AccurKardia, Inc. · Eatontown, New Jersey